首页> 外文期刊>Journal of nanoparticle research: An interdisciplinary forum for nanoscale science and technology >Mitochondrial-targeted DNA delivery using a DF-MITO-Porter, an innovative nano carrier with cytoplasmic and mitochondrial fusogenic envelopes
【24h】

Mitochondrial-targeted DNA delivery using a DF-MITO-Porter, an innovative nano carrier with cytoplasmic and mitochondrial fusogenic envelopes

机译:使用DF-MITO-Porter靶向线粒体的DNA递送,DF-MITO-Porter是一种具有细胞质和线粒体融合膜的创新纳米载体

获取原文
获取原文并翻译 | 示例
       

摘要

Mitochondrial gene therapy has the potential for curing a variety of diseases that are associated with mitochondrial DNA mutations and/or defects. To achieve this, it will be necessary to deliver therapeutic agents into the mitochondria in diseased cells. A number of mitochondrial drug delivery systems have been reported to date. However, reports of mitochondrial-targeted DNA delivery are limited. To achieve this, the therapeutic agent must be taken up by the cell (1), after which, the multi-processes associated with intracellular trafficking must be sophisticatedly regulated so as to release the agent from the endosome and deliver it to the cytosol (2) and to pass through the mitochondrial membrane (3). We report herein on the mitochondrial delivery of oligo DNA as a model therapeutic using a Dual Function (DF)-MITO-Porter, an innovative nano carrier designed for mitochondrial delivery. The critical structural elements of the DF-MITO-Porter include mitochondria-fusogenic inner envelopes and endosome-fusogenic outer envelopes, modified with octaarginine which greatly assists in cellular uptake. Inside the cell, the carrier passes through the endosomal and mitochondrial membranes via step-wise membrane fusion. When the oligo DNA was packaged in the DF-MITO-Porter, cellular uptake efficiency was strongly enhanced. Intracellular observation using confocal laser scanning microscopy showed that the DF-MITO-Porter was effectively released from endosomes. Moreover, the findings confirmed that the mitochondrial targeting activity of the DF-MITO-Porter was significantly higher than that of a carrier without outer endosome-fusogenic envelopes. These results support the conclusion that mitochondrial-targeted DNA delivery using a DF-MITO-Porter can be achieved when intracellular trafficking is optimally regulated.
机译:线粒体基因疗法具有治愈多种与线粒体DNA突变和/或缺陷相关的疾病的潜力。为此,有必要将治疗剂输送到患病细胞的线粒体中。迄今为止,已经报道了许多线粒体药物递送系统。但是,有关线粒体靶向DNA递送的报道有限。为此,治疗剂必须被细胞(1)吸收,此后,必须精确调节与细胞内运输相关的多个过程,以便从内体释放药物并将其递送至细胞质(2)。 )并穿过线粒体膜(3)。我们在此报告寡核苷酸DNA的线粒体递送,作为使用双重功能(DF)-MITO-Porter(一种设计用于线粒体递送的创新纳米载体)的模型治疗剂。 DF-MITO-Porter的关键结构要素包括线粒体融合体内部包膜和内体融合体外部包膜,并用八精氨酸修饰,大大有助于细胞摄取。在细胞内部,载体通过逐步的膜融合穿过内体膜和线粒体膜。当寡聚DNA包装在DF-MITO-Porter中时,细胞摄取效率被大大提高。使用共聚焦激光扫描显微镜的细胞内观察表明,DF-MITO-Porter可有效地从内体释放。此外,研究结果证实,DF-MITO-Porter的线粒体靶向活性显着高于无内体融合融合膜的载体。这些结果支持这样的结论,即当细胞内运输得到最佳调节时,可以使用DF-MITO-Porter进行线粒体靶向的DNA递送。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号